Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages

Kevin S. Ross, Harry A. Guess, H. Ballentine Carter

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Objectives. To estimate the declining benefits of screening for prostate cancer as patient age at screening increases. The benefits of prostate cancer screening decline with age because of the long natural history of prostate cancer and competing causes of death among older men. Methods. We used a previously described Monte Carlo simulation based on a Markov model of prostate cancer detection in men aged 40 to 90 years and simulated prostate cancer screening in 1000 populations of 1,000,000 men each. The age at the final prostate-specific antigen test in the model was varied to simulate the discontinuation of screening from age 50 to 80 years. The model outputs were the number of men treated, the number of prostate cancer deaths prevented by treatment, and person-years of life saved. Results. The relationship between treatments required to prevent a death was not constant but widened with age. Compared with screening to age 65 years, screening to age 75 and 80 years required twice and three times, respectively, the number of treatments per person-year of life saved. Conclusions. Our results have helped to quantify the declining treatment benefit as the patient age at screening and treatment for prostate cancer increases. We believe that men older than 70 years should be carefully counseled about the declining benefits of prostate cancer detection with screening.

Original languageEnglish (US)
Pages (from-to)1038-1042
Number of pages5
Issue number5
StatePublished - Nov 2005

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages'. Together they form a unique fingerprint.

Cite this